Intravesical botulinum toxin: results and impact on healthcare attendance in patients with overactive bladder
DOI:
https://doi.org/10.48193/ywrrz123Keywords:
Botulinum toxin, overactive bladder, medical visitsAbstract
Background: according to EUA and AUA guidelines, intradetrusor botulinum toxin A (TxBA) is a first-line alternative in cases of therapeutic failure, contraindications, intolerance to medication due to adverse effects, or refusal of conservative treatment for overactive bladder (OAB).
Objective: to assess the impact on visit frequency and the clinical and urodynamic characteristics of patients over 18 years of age undergoing intradetrusor botulinum toxin application in a functional urology service in Barcelona, Spain.
Patients and methods: descriptive, retrospective, observational study analyzing the medical records of patients undergoing botulinum toxin application, with a 2-year follow-up. Medical records were reviewed, and follow-up calls were made to all patients. Prior informed consent were signed, the medical records were reviewed, and follow-up calls were made to all patients. Descriptive and inferential statistics were used, statistical significance p value < 0.05.
Results: total of 23 non-neurogenic patients were studied, 62.5 % (15) women and 34.8 % (8) men, with a mean age of 63.52 ± 3.3 years. Prior to the application of TxBA, 78.3 % (18) had received anticholinergic treatment, and 47.8 % (11) had been treated with Mirabegron. The mean number of medical visits per year before TxBA was 4.0. Pre-TxBA evaluations showed a mean bladder capacity of 110.2 ± 25 ml, a daytime voiding frequency of 1.7 hours, and 2.86 nocturnal episodes per night. After a mean follow-up period of 12.21 months post-TxBA application, medical visits were reduced to 2.24 visits per year (p = 0.001). Symptomatic assessment revealed an increase in mean daytime voiding frequency to 2.8 ± 0.7 hours, accompanied by a decrease in nocturnal episodes to 1.9 ± 0.8 per night, both showing statistically significant reductions (p=0.001)
Conclusion: the application of intradetrusor botulinum toxin leads to a reduction in visit frequency in patients with overactive bladder. It is a safe procedure with few complications and symptom improvement.
References
Hung FC, Kuo HC. Liposome-Encapsulated Botulinum Toxin A in Treatment of Functional Bladder Disorders. Toxins. 2022;14(12): 838. https://doi.org/10.3390/toxins14120838.
Derisavifard S, Giusto LL, Zahner P, Rueb JJ, Goldman HB. Safety of Intradetrusor OnabotulinumtoxinA (BTX-A) Injection in the Asymptomatic Patient With a Positive Urine Dip. Urology. 2020;135: 38–43. https://doi.org/10.1016/j.urology.2019.09.030.
Errando-Smet C, Larrea G, Cidre J, Loveman C, Khalaf K, Aracil J, et al. A cost-effectiveness Analysis Of Onabotulinumtoxina For Overactive Bladder In Patients Who Are Inadequa℡Y Managed With Anticholinergic Medications In Spain. In: Neurourology And Urodynamics. Wiley-Blackwell 111 River St, Hoboken 07030-5774, NJ USA; 2014. p. 771–772.
Jiang YH, Liao CH, Kuo HC. Current and potential urological applications of botulinum toxin A. Nature Reviews. Urology. 2015;12(9): 519–533. https://doi.org/10.1038/nrurol.2015.193.
Drake MJ, Nitti VW, Ginsberg DA, Brucker BM, Hepp Z, McCool R, et al. Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU international. 2017;120(5): 611–622. https://doi.org/10.1111/bju.13945.
Murray B, Miles-Thomas J, Park AJ, Nguyen VB, Tung A, Gillard P, et al. Cost-effectiveness of overactive bladder treatments from a US commercial and payer perspective. Journal of Comparative Effectiveness Research. 2023;12(2): e220089. https://doi.org/10.2217/cer-2022-0089.
Del Popolo G, Gemma L. Intradetrusor botulinum toxin as the first-line treatment for neurogenic detrusor overactivity: Cons. Progres En Urologie: Journal De l’Association Francaise D’urologie Et De La Societe Francaise D’urologie. 2023;33(4): 176–177. https://doi.org/10.1016/j.purol.2022.12.008.
da Silva CM, Chancellor MB, Smith CP, Cruz F. Use of botulinum toxin for genitourinary conditions: What is the evidence? Toxicon: Official Journal of the International Society on Toxinology. 2015;107(Pt A): 141–147. https://doi.org/10.1016/j.toxicon.2015.07.333.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Revista Mexicana de Urología
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
